Join Growin Stock Community!

永昕4726.TW Overview

TW StockBiotech. & Medical
(No presentation for 4726)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

永昕（4726）Overall Performance

永昕（4726）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

永昕（4726） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

永昕（4726）Key Information

永昕（4726）Profile

Mycenax Biotech Inc. develops and manufactures biopharmaceutical products from mammalian and microbial cell lines in Taiwan, Europe, Asia, and the United States. The company develops monoclonal antibodies, bi-specific antibodies, fc-fusion proteins, recombinant proteins, peptides, protein conjugates (non-toxin), antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), as well as plasmids and DNA vaccines. It also provides process development solutions, including development of production cell lines, upstream and downstream process development, process scale-up, formulation development, and analytical methods; in-house analytical services; GMP manufacturing services, such as drug substance and products manufacturing, and cell banking; and manufacturing technologies. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.

永昕（4726）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

No related data records

default symbol

4726

永昕

32.50D

-0.15%

(-0.00)

  • When is 4726's latest earnings report released?

    The most recent financial report for 永昕 (4726) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4726's short-term business performance and financial health. For the latest updates on 4726's earnings releases, visit this page regularly.

  • What is the operating profit of 4726?

    According to the latest financial report, 永昕 (4726) reported an Operating Profit of -125.46M with an Operating Margin of -95.5% this period, representing a growth of 0.84% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 4726's revenue growth?

    In the latest financial report, 永昕 (4726) announced revenue of 131.37M, with a Year-Over-Year growth rate of -37.18%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 4726 have?

    At the end of the period, 永昕 (4726) held Total Cash and Cash Equivalents of 217.79M, accounting for 0.07 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4726 go with three margins increasing?

    In the latest report, 永昕 (4726) did not achieve the “three margins increasing” benchmark, with a gross margin of -49.67%%, operating margin of -95.5%%, and net margin of -98.86%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4726's profit trajectory and future growth potential.

  • Is 4726's EPS continuing to grow?

    According to the past four quarterly reports, 永昕 (4726)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.63. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 4726?

    永昕 (4726)'s Free Cash Flow (FCF) for the period is 55.49M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 73.84% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.